Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. | The Motley Fool
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.

Source: The Motley Fool
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.